These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 19761154)

  • 1. Fabry disease: a treatable lysosomal storage disorder.
    Phadke SR; Mandal K; Girisha KM
    Natl Med J India; 2009; 22(1):20-2. PubMed ID: 19761154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enzyme replacement therapy stabilizes obstructive pulmonary Fabry disease associated with respiratory globotriaosylceramide storage.
    Wang RY; Abe JT; Cohen AH; Wilcox WR
    J Inherit Metab Dis; 2008 Dec; 31 Suppl 2():S369-74. PubMed ID: 18937048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzyme Replacement Therapy for Lysosomal Storage Diseases.
    Kleppin S
    J Infus Nurs; 2020; 43(5):243-245. PubMed ID: 32881810
    [No Abstract]   [Full Text] [Related]  

  • 4. A diagnosis of Fabry gastrointestinal disease by chance: a case report.
    Feriozzi S; Torre ES; Ranalli TV; Cardello P; Morrone A; Ancarani E
    Eur J Gastroenterol Hepatol; 2007 Feb; 19(2):163-5. PubMed ID: 17273003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Agalsidase alfa: specific treatment for Fabry disease.
    Mehta A
    Hosp Med; 2002 Jun; 63(6):347-50. PubMed ID: 12096664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Diagnosis of Fabry disease: usefulness of the clinical investigation].
    Demontis R
    Rev Med Interne; 2010 Dec; 31 Suppl 2():S229-32. PubMed ID: 21211670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Fabry disease: new clinical research--current therapeutic perspectives].
    Beck M
    Wien Klin Wochenschr; 2003 Apr; 115(7-8):215-7. PubMed ID: 12778772
    [No Abstract]   [Full Text] [Related]  

  • 8. Anderson-Fabry disease in Austria.
    Lorenz M; Hauser AC; Püspök-Schwarz M; Kotanko P; Arias I; Zodl H; Kramar R; Paschke E; Voigtländer T; Sunder-Plassmann G
    Wien Klin Wochenschr; 2003 Apr; 115(7-8):235-40. PubMed ID: 12778775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Neurological manifestations of Fabry disease].
    Mendióroz M; Fernández-Cadenas I; Montaner J
    Rev Neurol; 2006 Dec 16-31; 43(12):739-45. PubMed ID: 17160925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anderson-Fabry disease: a protean clinical behavior and a chance diagnosis.
    Amico L; Visconti G; Amato A; Azzolina V; Sessa A; Li Vecchi M
    J Nephrol; 2005; 18(6):770-2. PubMed ID: 16358237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fabry disease: focus on cardiac manifestations and molecular mechanisms.
    Perrot A; Osterziel KJ; Beck M; Dietz R; Kampmann C
    Herz; 2002 Nov; 27(7):699-702. PubMed ID: 12439642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey.
    Ramaswami U; Whybra C; Parini R; Pintos-Morell G; Mehta A; Sunder-Plassmann G; Widmer U; Beck M;
    Acta Paediatr; 2006 Jan; 95(1):86-92. PubMed ID: 16498740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uneventful pregnancy outcome after enzyme replacement therapy with agalsidase beta in a heterozygous female with Fabry disease: A case report.
    Germain DP; Bruneval P; Tran TC; Balouet P; Richalet B; Benistan K
    Eur J Med Genet; 2010; 53(2):111-2. PubMed ID: 20045092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy.
    Desnick RJ; Brady R; Barranger J; Collins AJ; Germain DP; Goldman M; Grabowski G; Packman S; Wilcox WR
    Ann Intern Med; 2003 Feb; 138(4):338-46. PubMed ID: 12585833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histologic abnormalities of placental tissues in Fabry disease: a case report and review of the literature.
    Thurberg BL; Politei JM
    Hum Pathol; 2012 Apr; 43(4):610-4. PubMed ID: 22078290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fabry disease during childhood: clinical manifestations and treatment with agalsidase alfa.
    Ramaswami U
    Acta Paediatr; 2008 Apr; 97(457):38-40. PubMed ID: 18339186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful pregnancy outcome in a patient with Fabry disease receiving enzyme replacement therapy with agalsidase alfa.
    Wendt S; Whybra C; Kampmann C; Teichmann E; Beck M
    J Inherit Metab Dis; 2005; 28(5):787-8. PubMed ID: 16151910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stroke and Chronic Kidney Disease in Fabry Disease.
    Tapia D; Kimonis V
    J Stroke Cerebrovasc Dis; 2021 Sep; 30(9):105423. PubMed ID: 33160817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment with agalsidase beta during pregnancy in Fabry disease.
    Politei JM
    J Obstet Gynaecol Res; 2010 Apr; 36(2):428-9. PubMed ID: 20492401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enzyme replacement therapy of Fabry disease.
    Clarke JT; Iwanochko RM
    Mol Neurobiol; 2005 Aug; 32(1):43-50. PubMed ID: 16077182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.